Glycopyrrolate
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Peptic ulcer symptom reduction | Adults | Adjunctive (not monotherapy) | FDA Approved |
| Preoperative secretion reduction (salivary, tracheobronchial, pharyngeal) | Adults and pediatric patients (≥1 month) | Perioperative adjunct | FDA Approved |
| Intraoperative vagal reflex-associated arrhythmias | Adults and pediatric patients | Intraoperative adjunct | FDA Approved |
| Reversal of neuromuscular blockade — protection against muscarinic effects of neostigmine/pyridostigmine | Adults and pediatric patients | Adjunctive with anticholinesterase | FDA Approved |
| Chronic severe drooling (sialorrhea) associated with neurologic conditions (e.g., cerebral palsy) | Children 3–16 years | Monotherapy | FDA Approved |
Glycopyrrolate is a versatile anticholinergic agent used across perioperative, gastrointestinal, and pediatric neurology settings. Its quaternary ammonium structure limits blood-brain barrier penetration, conferring a lower incidence of central nervous system adverse effects compared with tertiary amine antimuscarinics such as atropine. In perioperative practice, it remains widely used as a premedication to reduce secretions and as the preferred anticholinergic co-administered with neostigmine for reversal of neuromuscular blockade. The oral solution formulation (Cuvposa) addressed a significant unmet need for managing drooling in children with neurologic impairment.
Hyperhidrosis (topical glycopyrronium tosylate is FDA-approved separately as Qbrexza; oral/injectable glycopyrrolate is sometimes used off-label): Evidence quality — Moderate. Small studies and clinical experience support oral glycopyrrolate for refractory hyperhidrosis, though the topical formulation is preferred when focal treatment is appropriate.
Death rattle (terminal secretions) in palliative care: Evidence quality — Low. Used subcutaneously in hospice settings to reduce noisy upper airway secretions in dying patients, though randomised evidence is limited and benefit may be modest.
Clozapine-induced sialorrhea: Evidence quality — Low. Case series and expert consensus support glycopyrrolate for reducing clozapine-associated hypersalivation when dose adjustment is not feasible.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Peptic ulcer — symptom control, initial therapy | 1 mg TID | 1 mg BID | 8 mg/day | Some patients need 2 mg at bedtime for overnight control Adjunctive only; not effective as peptic ulcer monotherapy |
| Peptic ulcer — established disease, higher dose regimen | 2 mg BID–TID | 2 mg BID–TID | 8 mg/day | Use lowest effective dose; step down to 1 mg formulation when possible Dartisla ODT 1.7 mg is bioequivalent to 2 mg tablet |
| Preoperative secretion reduction — adult | 0.004 mg/kg IM | Single dose | 0.004 mg/kg | Give 30–60 min before induction May also be given at time of preanesthetic opioid/sedative |
| Intraoperative arrhythmia — vagal reflex | 0.1 mg IV | Repeat q2–3 min PRN | No explicit max; titrate to response | Onset within 1 min IV; address underlying cause of arrhythmia concurrently |
| Reversal of neuromuscular blockade — with neostigmine | 0.2 mg per 1 mg neostigmine | Single co-administration | Per neostigmine dose | Administer simultaneously IV; alternatively 0.2 mg per 5 mg pyridostigmine |
| Peptic ulcer — IV/IM when oral not feasible | 0.1 mg IV/IM q4h | 0.1–0.2 mg q4h | 0.2 mg q4h (QID) | Frequency dictated by response; some patients need only a single dose |
Pediatric Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Chronic severe drooling (sialorrhea) — ages 3–16 | 0.02 mg/kg TID | Titrate by 0.02 mg/kg q5–7 days | 0.1 mg/kg TID (max 1.5–3 mg/dose by weight) | Give 1 h before or 2 h after meals High-fat food substantially reduces absorption |
| Preoperative secretion reduction — ages 1 month to 2 years | 0.004–0.009 mg/kg IM | Single dose | 0.009 mg/kg | Give 30–60 min before induction Infants may require higher weight-based doses than older children |
| Preoperative secretion reduction — ages >2 years | 0.004 mg/kg IM | Single dose | 0.004 mg/kg | Same timing as adult premedication |
For Cuvposa (oral solution for drooling), titration occurs over 4 weeks. Before each dose increase, assess tolerability of the current level with the caregiver. Constipation is the most common dose-limiting adverse effect and typically appears within 4–5 days of a dose change. In the perioperative setting, glycopyrrolate is preferred over atropine when co-administered with neostigmine because it produces less tachycardia, does not cross the blood-brain barrier, and has a longer antisialagogue effect (up to 7 hours versus 4 hours for atropine).
Pharmacology
Mechanism of Action
Glycopyrrolate is a synthetic quaternary ammonium antimuscarinic agent that competitively inhibits acetylcholine at muscarinic receptors on smooth muscle, cardiac muscle, the sinoatrial and atrioventricular nodes, exocrine glands, and autonomic ganglia. By blocking muscarinic stimulation of salivary glands, it reduces the volume of saliva and pharyngeal secretions. At gastric parietal cells, it decreases the volume and free acidity of gastric secretions. Its vagolytic action at the sinoatrial node counteracts bradycardia triggered by surgical manipulation or cholinergic agents. Because glycopyrrolate is fully ionised at physiological pH, it does not appreciably cross the blood-brain barrier, resulting in substantially fewer central nervous system effects than tertiary amine antimuscarinics such as atropine or scopolamine.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability ~3% (range 1.3–13.3%); Tmax ~3 h (oral); high-fat meal reduces absorption significantly | Must dose on an empty stomach (1 h before or 2 h after meals); low and variable oral bioavailability makes parenteral route more predictable |
| Distribution | Vd 0.42 ± 0.22 L/kg (adults IV); 1.3–1.8 L/kg (children 1–14 y); does not cross BBB | Larger Vd in children may necessitate weight-based dosing; absent CNS penetration reduces risk of confusion and agitation |
| Metabolism | Minimal hepatic metabolism; >80% of radioactivity in urine corresponds to unchanged drug | No significant CYP involvement; hepatic impairment unlikely to alter exposure meaningfully, though formal data are lacking |
| Elimination | 65–80% excreted unchanged in urine; t½ ~18.6 min (IV adults), ~46.8 min (renal failure IV), ~2.8 h (oral); <5% biliary | Severely prolonged elimination in renal failure (t½ increases >2-fold); dose reduction or monitoring essential in renal impairment |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dry mouth | 40% | Most common anticholinergic effect; dose-dependent; advise frequent sips of water and sugar-free gum |
| Vomiting | 40% | Particularly reported in pediatric sialorrhea trials; usually improves with dose stabilisation |
| Constipation | 35% | Dose-limiting; assess within 4–5 days of each dose change; may require laxative co-prescription |
| Flushing | 30% | Due to impaired thermoregulation from reduced sweating; more pronounced in warm environments |
| Nasal congestion | 30% | Drying of nasal mucosa with rebound congestion; usually mild and self-limiting |
Incidence data from the Cuvposa (oral solution) placebo-controlled trial (N=20 active, N=18 placebo). Rates for injectable and oral tablet formulations are reported differently due to postmarketing voluntary reporting (see below).
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Urinary retention | 15% | Monitor urine output especially in patients with prostatic hypertrophy; may present as dry diapers in children |
| Headache | 15% | Transient; usually mild and does not require dose adjustment |
| Sinusitis | 15% | May be related to mucosal drying; distinguish from upper respiratory infection |
| Upper respiratory tract infection | 15% | Reported in pediatric trials; likely related to study population rather than direct drug effect |
| Tachycardia | Reported (frequency not precisely quantified) | Dose-related; less than atropine due to quaternary structure; monitor in cardiac patients |
| Blurred vision / mydriasis | Reported (frequency not precisely quantified) | Warn patients; avoid driving or hazardous activities if visual impairment occurs |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Intestinal pseudo-obstruction | Rare | Days to weeks after initiation | Discontinue immediately; abdominal imaging; surgical consultation if needed |
| Heat prostration (hyperthermia) | Rare | With high ambient temperature | Active cooling; discontinue drug; particular caution in children and elderly |
| Acute angle-closure glaucoma | Very rare | Hours to days | Immediate ophthalmology referral; discontinue glycopyrrolate; topical miotics |
| Anaphylaxis / hypersensitivity | Very rare | Minutes to hours | Standard anaphylaxis management; permanent discontinuation |
| Paralytic ileus / toxic megacolon | Very rare | Days to weeks, especially in ulcerative colitis patients | Discontinue; surgical emergency assessment; contraindicated in severe ulcerative colitis |
| Anticholinergic toxicity syndrome (agitation, seizures, hyperthermia in overdose) | Very rare (overdose setting) | Hours post-overdose | Supportive care; consider physostigmine under toxicology guidance; contact Poison Control |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Constipation | Most common dose-limiting effect | Assess within 4–5 days of dose initiation or increase; often requires laxative or dose reduction |
| Dry mouth | Common contributor | May impair quality of life; sugar-free gum and saliva substitutes can help |
| Urinary retention | Occasional | Particularly in patients with prostatic hypertrophy or neurogenic bladder |
Constipation is the most clinically significant adverse effect of glycopyrrolate and the most common reason for treatment discontinuation, particularly in the pediatric sialorrhea population. Caregivers should be counselled to assess bowel habits within 4–5 days of starting or increasing the dose. If constipation develops, the drug should be withheld and the prescriber contacted before resuming at the prior dose level. Prophylactic stool softeners (e.g., polyethylene glycol) may be considered in patients predisposed to constipation, though evidence specifically for glycopyrrolate co-prescription is limited.
Drug Interactions
Glycopyrrolate undergoes minimal hepatic metabolism and is not a substrate or inhibitor of cytochrome P450 enzymes. The principal interaction risks are pharmacodynamic (additive anticholinergic effects) and absorption-related (altered GI transit affecting co-administered drugs). No CYP-mediated drug-drug interactions are expected.
Monitoring
-
Bowel Function
Within 4–5 days of each dose change, then ongoing
Routine Assess stool frequency and consistency. Constipation is the most common dose-limiting effect. Withhold drug and contact prescriber if constipation develops before resuming at a lower dose. -
Urinary Output
Each visit; ongoing
Routine Monitor for urinary retention, especially in patients with prostatic hypertrophy or neurogenic bladder. In non-verbal children, dry diapers or irritability may indicate retention. -
Heart Rate
Perioperative; with dose changes
Routine Vagolytic effects can cause tachycardia. Particular attention in patients with coronary artery disease, heart failure, or cardiac arrhythmias. -
Renal Function
Baseline, then periodically
Routine Glycopyrrolate is predominantly renally eliminated. In renal failure, half-life is prolonged more than 2-fold. Monitor for accumulation and anticholinergic toxicity; consider dose reduction. -
Intraocular Pressure
If eye symptoms develop
Trigger-based Anticholinergics may precipitate acute angle-closure glaucoma. Instruct patients to seek immediate care for eye pain with redness and dilated pupils. -
Body Temperature
During high ambient temperatures
Trigger-based Reduced sweating increases heat prostration risk. Advise caregivers to keep children cool and hydrated during warm weather. Elderly are also at elevated risk. -
Cognitive Function
If symptoms develop
Trigger-based Though CNS penetration is minimal, drowsiness and blurred vision can occur. Discontinue if cognitive or visual impairment develops. Evaluate anticholinergic burden in elderly patients taking multiple agents.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to glycopyrrolate or any inactive ingredient
- Angle-closure glaucoma (may increase intraocular pressure)
- Obstructive uropathy including bladder neck obstruction due to prostatic hypertrophy
- Mechanical GI obstruction (pyloroduodenal stenosis, strictures)
- GI motility disorders: achalasia, paralytic ileus, intestinal atony
- Bleeding gastrointestinal ulcer
- Active inflammatory or infectious colitis that could lead to toxic megacolon
- History of or current toxic megacolon
- Myasthenia gravis (may worsen muscular weakness)
- Concomitant solid oral potassium chloride (risk of GI erosion)
Relative Contraindications (Specialist Input Recommended)
- Severe renal impairment: Elimination is markedly prolonged; if used, requires close monitoring and likely dose reduction
- Unstable cardiovascular status in acute haemorrhage
- Severe ulcerative colitis: Large doses may suppress intestinal motility sufficiently to precipitate paralytic ileus or toxic megacolon
- Elderly patients on multiple anticholinergics: Cumulative anticholinergic burden increases risk of falls, confusion, and urinary retention
Use with Caution
- Autonomic neuropathy
- Hyperthyroidism (anticholinergics may exacerbate tachycardia)
- Coronary heart disease, heart failure, tachyarrhythmias
- Hiatal hernia with reflux oesophagitis (may worsen reflux)
- Hepatic disease (no formal PK data; use with caution)
- Down syndrome and pediatric patients with brain damage or spastic paralysis (increased sensitivity to anticholinergic effects; may cause hyperexcitability at high doses)
- Infants (<1 month for injectable; <3 years for oral solution)
Glycopyrrolate reduces sweating, which can lead to dangerous hyperthermia (heat stroke) during exposure to high ambient temperatures. This risk is particularly elevated in children who cannot communicate symptoms and in elderly patients with impaired thermoregulation. Caregivers should be counselled to avoid exposing patients to hot environments and to ensure adequate hydration during warm weather.
Patient Counselling
Purpose of Therapy
Glycopyrrolate works by blocking a chemical messenger called acetylcholine, which controls secretions from glands and the movement of muscles in the digestive tract. Depending on the indication, it is used to reduce excessive saliva (drooling) in children with neurological conditions, to decrease stomach acid secretion in peptic ulcer disease, or to reduce airway secretions and prevent heart rate drops during surgery. The drug begins working within minutes when given intravenously and within 30–60 minutes when given intramuscularly. Oral formulations have a slower onset but provide sustained antisecretory effects throughout the dosing interval.
How to Take
For oral solution (Cuvposa): Measure each dose using a graduated dosing cup and administer with an oral syringe into the child’s mouth. Give at least 1 hour before or 2 hours after meals, as food (especially fatty meals) substantially reduces drug absorption. For oral tablets: Take as directed by your prescriber, typically three times daily with the morning, early afternoon, and bedtime doses. For Dartisla ODT: Place the orally disintegrating tablet on the tongue and allow it to dissolve; do not chew or swallow whole.
Sources
- Cuvposa (glycopyrrolate) oral solution prescribing information. Merz Pharmaceuticals, LLC. Revised 02/2018. FDA Label Primary source for pediatric sialorrhea dosing, adverse reaction rates from pivotal trial (Study FH-00-01), and drug interaction data.
- Glycopyrrolate Injection, USP prescribing information. Revised 2024. FDA Label Source for injectable dosing (preoperative, intraoperative, reversal of neuromuscular blockade), pharmacokinetics including renal impairment data.
- Robinul and Robinul Forte (glycopyrrolate) tablets prescribing information. Concordia Pharmaceuticals. Revised 2022. FDA Label Source for oral tablet dosing in peptic ulcer disease, contraindications, and adult use precautions.
- Dartisla ODT (glycopyrrolate) orally disintegrating tablets prescribing information. Edenbridge Pharmaceuticals. 2021. FDA Label Source for ODT formulation bioequivalence data (1.7 mg ODT comparable to 2 mg tablet) and oral pharmacokinetics.
- Zeller RS, Lee HM, Engel SH, et al. Randomized Phase III evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic severe drooling in children with cerebral palsy or other neurologic conditions. Ther Clin Risk Manag. 2012;8:15-23. DOI Pivotal placebo-controlled trial (Study FH-00-01) establishing Cuvposa efficacy; source for adverse reaction incidence rates used in side effects section.
- Mier RJ, Bachrach SJ, Lakin RC, et al. Treatment of sialorrhea with glycopyrrolate: a double-blind, dose-ranging study. Arch Pediatr Adolesc Med. 2000;154(12):1214-1218. DOI Early dose-ranging trial in children demonstrating dose-response relationship for drooling reduction with glycopyrrolate.
- CADTH Clinical Review Report: Glycopyrrolate Oral Solution (Cuvposa). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020. NCBI Bookshelf Systematic review of glycopyrrolate evidence for pediatric sialorrhea, including critical appraisal of Study FH-00-01 and open-label extension data.
- Medsafe New Zealand. Glycopyrronium Data Sheet. Updated 2023. Medsafe International regulatory perspective on glycopyrronium bromide; useful for cross-referencing dosing recommendations outside US labelling.
- Mirakhur RK, Dundee JW. Glycopyrrolate: pharmacology and clinical use. Anaesthesia. 1983;38(12):1195-1204. DOI Comprehensive early review of glycopyrrolate pharmacology, establishing the rationale for its quaternary ammonium structure and limited CNS penetration.
- Ali-Melkkilä T, Kanto J, Iisalo E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand. 1993;37(7):633-642. DOI Comparative pharmacokinetic analysis of glycopyrrolate versus atropine and scopolamine, clarifying duration of vagolytic and antisialagogue effects.
- Kirvelä O, Ali-Melkkilä T, Kaila T, et al. Pharmacokinetics of glycopyrronium in uraemic patients. Br J Anaesth. 1993;71(3):437-439. DOI Key study demonstrating that glycopyrrolate half-life is prolonged from 18.6 to 46.8 minutes in uremic patients; basis for renal dose adjustment recommendations.
- Rautakorpi P, Ali-Melkkilä T, Kaila T, et al. Pharmacokinetics of glycopyrrolate in children. J Clin Anesth. 1994;6(3):217-220. DOI Pediatric PK study showing larger volume of distribution (1.3-1.8 L/kg) in children compared with adults (0.42 L/kg), informing weight-based dosing.